Royalty Pharma (RPRX) Q4 2025 earnings summary

Executive summary

• Achieved double-digit growth in 2025, with Portfolio Receipts up 16% to $3,254M and Royalty Receipts up 13%, driven by strong capital deployment and portfolio performance.

• Internalized external manager, eliminating management fees, improving alignment, governance, and cost structure.

• Returned $1.7B to shareholders via $1.2B in share repurchases and over $500M in dividends; increased dividend by 7% in Q1 2026.

• Announced $4.7B in royalty transactions across 9 therapies, with a record year for synthetic royalty deals.

• Positive clinical and regulatory updates for key therapies, including FDA approvals and Phase 3 results for Myqorzo, Tremfya, TEV-'749, deucrictibant, and Trodelvy.

Financial highlights

• FY 2025 Portfolio Receipts were $3,254M (+16% YoY) and Royalty Receipts $3,127M (+13% YoY); Q4 Portfolio Receipts $874M (+18% YoY), Royalty Receipts $856M (+17% YoY).

• Adjusted EBITDA for FY 2025 was $2,966M (91.1% of Portfolio Receipts); Portfolio Cash Flow $2,724M (83.7% of Portfolio Receipts).

• Return on Invested Capital was 15.8% and Return on Invested Equity was 22.8% for 2025.

• Ended 2025 with $619M in cash and $9.2B in investment-grade debt; leverage at 3.0x total debt to Adjusted EBITDA.

• Net income attributable to shareholders was $771M for FY 2025.

Outlook and guidance

• 2026 guidance: Portfolio Receipts of $3,275M–$3,425M, Royalty Receipts growth of 3%–8%.

• Operating and professional costs expected to drop to 5.5%–6.5% of Portfolio Receipts in 2026 due to internalization.

• Interest paid expected to rise to $350M–$360M in 2026 due to new notes issued.

• Guidance reflects loss of exclusivity for Promacta, biosimilar Tysabri launch, and IRA impact.

• Milestones and other contractual receipts expected to decrease from $128M in 2025 to $60M in 2026.